KPV is a very short peptide studied mainly for anti-inflammatory activity,
particularly in the gut.
Chemical identity & structure.
KPV is a tripeptide — just three amino acids, lysine-proline-valine. It
corresponds to the C-terminal three-residue fragment of alpha-melanocyte-
stimulating hormone (α-MSH). It is one of the shortest peptides in this library.
Mechanism of action.
KPV is reported to carry the anti-inflammatory activity of the parent α-MSH
peptide without the pigmentation effects, because it lacks the part of the
α-MSH sequence responsible for melanocortin-receptor pigmentation signaling. The
reported anti-inflammatory mechanisms include effects on inflammatory signaling
pathways inside cells; some research suggests KPV can act intracellularly. These
mechanisms are reported from preclinical work and are not fully settled.
Key research findings.
Preclinical research — cell and rodent models — has reported anti-inflammatory
effects, with notable interest in models of intestinal inflammation
(inflammatory bowel disease models). Topical and wound-related anti-inflammatory
research also appears in the literature.
The research / citation base.
The KPV literature is predominantly preclinical. There is little
substantial human clinical-trial data, and KPV is not an approved drug. Its
human safety and efficacy profile is not established. The preclinical
gut-inflammation work is the most-cited part of its evidence base.
Human clinical trial data.
No human clinical trial has established administration parameters for KPV; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
As a simple tripeptide, KPV is straightforward to verify — a batch-specific COA
should report mass-spectrometry identity and HPLC purity.
*Research-use note: Educational summary of published research. KPV is not an
approved drug; this is research context only and not medical advice.*